GW4064: Selective Non-Steroidal FXR Agonist for Metabolic Research

Executive Summary: GW4064 is a high-affinity, non-steroidal agonist targeting the farnesoid X receptor (FXR), crucial for the regulation of bile acid, lipid, and glucose metabolism (APExBIO product page). It exhibits an EC50 of 15 nM in isolated receptor assays and 90 nM in human FXR-transfected cells, supporting its potency and selectivity. FXR activation by GW4064 leads to decreased triglyceride and VLDL secretion in multiple rodent models. The compound’s poor water and ethanol solubility, UV instability, and stilbene pharmacophore toxicity restrict its use to in vitro and preclinical research. Recent studies leverage GW4064 to dissect the FXR/TLR4/ferroptosis axis, illuminating its role in fibrotic and metabolic disease models (Zhou et al., 2025).

Biological Rationale

The farnesoid X receptor (FXR; NR1H4) is a ligand-activated nuclear receptor that governs bile acid synthesis, lipid homeostasis, and glucose metabolism. FXR is highly expressed in the liver, intestine, kidney, and adrenal glands. Dysregulation of FXR signaling is implicated in metabolic disorders, including non-alcoholic fatty liver disease (NAFLD), dyslipidemia, and fibrosis (Zhou et al., 2025). Pharmacological activation of FXR offers a strategic entry point to investigate these pathological mechanisms and their modulation in preclinical systems.

Mechanism of Action of GW4064

GW4064 is a synthetic, non-steroidal agonist that binds the ligand-binding domain of FXR with high affinity. It is chemically defined as 3-[(E)-2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]phenyl]ethenyl]benzoic acid (APExBIO B1527). Upon binding, GW4064 induces a conformational shift in FXR, facilitating coactivator recruitment and transcriptional regulation of target genes, such as SHP, BSEP, and CYP7A1. This cascade alters bile acid transport, inhibits triglyceride synthesis, and suppresses hepatic gluconeogenesis. GW4064 is insoluble in water and ethanol but dissolves in DMSO at ≥24.7 mg/mL. It is UV-unstable and requires storage at -20°C for optimal stability.

Evidence & Benchmarks

• GW4064 activates human FXR with an EC50 of 90 nM in cell-based assays (APExBIO).
• In KK-Ay and ob/ob mice, GW4064 treatment reduces serum triglyceride and VLDL levels, demonstrating efficacy in metabolic disease models (Zhou et al., 2025).
• GW4064 modulates the FXR/TLR4 pathway and augments ferroptosis markers, leading to decreased collagen deposition in nickel oxide nanoparticle-exposed LX-2 cells (Zhou et al., 2025).
• Compared to vehicle, GW4064 significantly increased FXR target gene expression (e.g., SHP, BSEP) within 24 hours in primary hepatocyte cultures (internal article).
• GW4064 is ineffective in vivo when administered in aqueous or ethanol-based vehicles due to its insolubility (APExBIO).

Applications, Limits & Misconceptions

GW4064 is primarily employed as a research tool to elucidate:

• FXR’s role in cholesterol, triglyceride, and bile acid metabolism.
• The FXR/TLR4 axis in liver fibrosis and inflammatory signaling.
• Mechanisms underlying ferroptosis in hepatic stellate cell activation.

This article extends the mechanistic focus of the GW4064 in Metabolic Disorder Research resource by directly mapping FXR activation to the ferroptosis and collagen deposition endpoints in hepatic models.

Common Pitfalls or Misconceptions

• GW4064 is not suitable for therapeutic use due to poor solubility, UV instability, and potential stilbene-driven toxicity (APExBIO).
• Water or ethanol-based formulations do not yield biologically active GW4064 in vivo (APExBIO).
• Effects observed with GW4064 may not generalize to all FXR ligands, as pharmacokinetic and off-target profiles differ (internal article).
• GW4064 is not a pan-nuclear receptor agonist; it is highly selective for FXR (APExBIO).
• Long-term GW4064 solutions are unstable; fresh DMSO preparations are required for consistent results.

Workflow Integration & Parameters

GW4064 is provided as a solid, with a molecular weight of 542.85 (C28H22Cl3NO4). Researchers should solubilize it in DMSO to concentrations up to 24.7 mg/mL. Stock solutions must be aliquoted and stored at -20°C, protected from light. For in vitro studies, typical working concentrations range from 10 nM to 10 μM, with exposure durations from 2 to 48 hours depending on the cell model and endpoint. In animal studies, vehicle selection is critical to maximize bioavailability; DMSO-based vehicles are preferred. The B1527 kit from APExBIO provides quality assurance for reproducible results (GW4064 product page).

For further protocol optimization and troubleshooting, the article GW4064: Advanced Insights into FXR Signaling and Metabolic Pathways reviews solvent compatibility and advanced dosing regimens. The present article integrates recent findings on the FXR/TLR4/ferroptosis axis, providing a mechanistic update beyond standard protocols.

Conclusion & Outlook

GW4064 is a gold-standard tool compound for dissecting FXR-driven metabolic and fibrotic processes. Its high potency and selectivity allow for precise modulation of FXR signaling in preclinical models. Limitations such as solubility and photoinstability restrict its translational potential but do not diminish its value in foundational research. Future work may focus on developing next-generation FXR agonists with improved pharmacological properties, building on the mechanistic insights derived from GW4064-based studies. For a strategic perspective on advancing FXR-targeted research and addressing tool compound limitations, see Translating FXR Signaling into Actionable Insights, which this article updates with new evidence on the ferroptosis pathway.